Emily Mooers, Satyan Lakshiminrusimha, G. Ganesh Konduri
Medical College of Wisconsin and Children’s Wisconsin. University of California and UC Davis Children’s Hospital.
United States
Clinics in Perinatology
Clin Perinatol 2026; 53: 297-316
DOI: 10.1016/j.clp.2026.02.003
Abstract
This article details an integrated approach to optimize management strategies for hypoxemic respiratory failure and hemodynamic instability in persistent pulmonary hypertension of the newborn (PPHN). Even with adequate lung recruitment, inhaled nitric oxide, the only food and drug administration (FDA)-approved therapy for PPHN, fails in one-third of cases. Animal models of PPHN have enhanced understanding of PPHN pathophysiology, resulting in new targets for the development of alternative vasodilators, including phosphodiesterase inhibitors, prostaglandins, and endothelin antagonists. However, support of these therapies is limited to observational studies. Our article summarizes the available evidence for using such alternative vasodilators in PPHN infants.
Category
Class I. Persistent Pulmonary Hypertension of the Newborn
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No